Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex
- PMID: 12644465
- DOI: 10.1074/jbc.M301567200
Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex
Abstract
Ligand binding by Notch receptors triggers a series of proteolytic cleavages that liberate the intracellular portion of Notch (ICN) from the cell membrane, permitting it to translocate to the nucleus. Nuclear ICN binds to a highly conserved DNA-binding transcription factor called CSL (also known as RBP-Jkappa, CBF1, Suppressor of Hairless, and Lag-1) and recruits Mastermind-like transcriptional co-activators to form a transcriptional activation complex. Using bioinformatics tools, we identified a Rel homology region (RHR) within CSL that was used as a guide to determine the minimal protein requirements for ternary complex formation. The RHR of CSL contains both the N- and C-terminal beta-sheet domains (RHR-n and RHR-c) of typical Rel transcription factors, as judged by circular dichroism spectra. Binding of monomeric CSL to DNA requires the entire RHR of CSL and an additional 125-residue N-terminal sequence, whereas binding to ICN requires only the RHR-n domain. Although the RAM (RBP-Jkappa (recombination-signal-sequence-binding protein for Jkappa genes)-associated molecule) domain of ICN is flexible and relatively unstructured as an isolated polypeptide in solution, it associates stably with CSL on DNA. Recruitment of Mastermind-like 1 (MAML1) to CSL.ICN complexes on DNA requires inclusion of the ankyrin repeat domain of ICN, and N- and C-terminal sequences of CSL extending beyond the DNA-binding region. The requirement for cooperative assembly of the MAML1.ICN.CSL.DNA complex suggests that a primary function of ICN is to render CSL competent for MAML loading. On the basis of our results, we present a working structural model for the organization of the MAML1.ICN.CSL.DNA complex.
Similar articles
-
Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors.Mol Cell Biol. 2002 Nov;22(21):7688-700. doi: 10.1128/MCB.22.21.7688-7700.2002. Mol Cell Biol. 2002. PMID: 12370315 Free PMC article.
-
Notch and MAML-1 complexation do not detectably alter the DNA binding specificity of the transcription factor CSL.PLoS One. 2010 Nov 24;5(11):e15034. doi: 10.1371/journal.pone.0015034. PLoS One. 2010. PMID: 21124806 Free PMC article.
-
Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA.Cell. 2006 Mar 10;124(5):985-96. doi: 10.1016/j.cell.2006.01.035. Cell. 2006. PMID: 16530045
-
More complicated than it looks: assembly of Notch pathway transcription complexes.Oncogene. 2008 Sep 1;27(38):5099-109. doi: 10.1038/onc.2008.223. Oncogene. 2008. PMID: 18758478 Review.
-
The effects of conformational heterogeneity on the binding of the Notch intracellular domain to effector proteins: a case of biologically tuned disorder.Biochem Soc Trans. 2008 Apr;36(Pt 2):157-66. doi: 10.1042/BST0360157. Biochem Soc Trans. 2008. PMID: 18363556 Review.
Cited by
-
Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA.EMBO J. 2004 Sep 1;23(17):3441-51. doi: 10.1038/sj.emboj.7600349. Epub 2004 Aug 5. EMBO J. 2004. PMID: 15297877 Free PMC article.
-
Targeting Notch to target cancer stem cells.Clin Cancer Res. 2010 Jun 15;16(12):3141-52. doi: 10.1158/1078-0432.CCR-09-2823. Epub 2010 Jun 8. Clin Cancer Res. 2010. PMID: 20530696 Free PMC article. Review.
-
NELFE promoted pancreatic cancer metastasis and the epithelial‑to‑mesenchymal transition by decreasing the stabilization of NDRG2 mRNA.Int J Oncol. 2019 Dec;55(6):1313-1323. doi: 10.3892/ijo.2019.4890. Epub 2019 Oct 2. Int J Oncol. 2019. PMID: 31638184 Free PMC article.
-
Eliciting the T cell fate with Notch.Semin Immunol. 2010 Oct;22(5):254-60. doi: 10.1016/j.smim.2010.04.011. Epub 2010 Jun 2. Semin Immunol. 2010. PMID: 20627765 Free PMC article. Review.
-
Identification of Potential RBPJ-Specific Inhibitors for Blocking Notch Signaling in Breast Cancer Using a Drug Repurposing Strategy.Pharmaceuticals (Basel). 2022 Apr 29;15(5):556. doi: 10.3390/ph15050556. Pharmaceuticals (Basel). 2022. PMID: 35631382 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
